Myocarditis following adeno-associated viral gene expression of human soluble TNF receptor (TNFRII-Fc) in baboon hearts

Gene Therapy

Volumn 14, Issue 23, 2007, Pages 1613-1622

  McTiernan, C F ^a   Mathier, M A ^a   Zhu, X ^a   Xiao, X ^b   Klein, E ^a   Swan, C H ^a   Mehdi, H ^a   Gibson, G ^a   Trichel, A M ^a   Glorioso, J C ^a   Feldman, A M ^c   McCurry, K R ^d   London, B ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; HYBRID PROTEIN; PARVOVIRUS VECTOR; TUMOR NECROSIS FACTOR RECEPTOR 2; TUMOR NECROSIS FACTOR RECEPTOR 2 FC FUSION PROTEIN; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ADENO ASSOCIATED VIRUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BABOON; BIOSAFETY; BLOOD CELL COUNT; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL CHEMISTRY; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; GENE EXPRESSION; GENE SEQUENCE; GENE THERAPY; GENETIC TRANSCRIPTION; LYMPHOCYTIC INFILTRATION; MALE; MYOCARDITIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; T WAVE; VIRAL GENE DELIVERY SYSTEM; VIRUS CAPSID; VIRUS GENOME;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; DEPENDOVIRUS; GENE THERAPY; GENETIC VECTORS; IMMUNOGLOBULIN FC FRAGMENTS; INJECTIONS; MALE; MICROSCOPY, FLUORESCENCE; MODELS, ANIMAL; MYOCARDITIS; MYOCARDIUM; PAPIO; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; RECOMBINANT FUSION PROTEINS;

ADENO-ASSOCIATED VIRUS; ADENO-ASSOCIATED VIRUS - 2; MIRIDAE; PAPIO; RODENTIA;

EID: 36349001686     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3303020     Document Type: Article

References (34)

1. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: A report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Card 1996; 27: 1201-1206.
2. Feldman AM, Combes A, Wagner D, Kadakomi T, Kubota T, Li YY et al. The role of tumor necrosis factor in the pathophysiology of heart failure. J Am Coll Card 2000; 35: 537-544.
3. Kubota T, McTiernan CF, Frye CS, Slawson SE, Lemster BH, Koretsky AP et al. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res 1997; 81: 627-635.
4. Li D, Zhao L, Liu M, Du X, Ding W, Zhang J et al. Kinetics of tumor necrosis factor alpha in plasma and the cardioprotective effect of a monoclonal antibody to tumor necrosis factor alpha in acute myocardial infarction. Am Heart J 1999; 137: 1145-1152.
5. Higuchi Y, McTiernan CF, Frye CB, McGowan BS, Chan TO, Feldman AM. Tumor necrosis factor receptors 1 and 2 differentially regulate survival, cardiac dysfunction, and remodeling in transgenic mice with tumor necrosis factor-alpha-induced cardiomyopathy. Circulation 2004; 109: 1892-1897.
6. Ramani R, Mathier M, Wang P, Gibson G, Togel S, Dawson J et al. Inhibition of tumor necrosis factor receptor-1-mediated pathways has beneficial effects in a murine model of postischemic remodeling. Am J Physiol 2004; 287: H1369-H1377.
7. Kubota T, Bounoutas GS, Miyagishima M, Kadokami T, Sanders VJ, Bruton C et al. Soluble tumor necrosis factor receptor abrogates myocardial inflammation but not hypertrophy in cytokine-induced cardiomyopathy. Circulation 2000; 101: 2518-2525.
8. Sugano M, Koyanagi M, Tsuchida K, Hata T, Makino N. In vivo gene transfer of soluble TNF-alpha receptor 1 alleviates myocardial infarction. FASEB J 2002; 16: 1421-1422.
9. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997; 337: 141-147.
10. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349: 2014-20222.
11. Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS et al. Targeted anticytokine therapy in-patients with chronic heart failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004; 109: 1594-1602.
12. Su H, Lu R, Kan YW. Adeno-associated viral vector-mediated vascular endothelial growth factor gene transfer induces neovascular formation in ischemic heart. Proc Nat Acad Sci USA 2000; 97: 13801-13806.
13. Zhu T, Zhou L, Mori S, Wang Z, McTiernan CF, Qiao C et al. Sustained whole-body functional rescue in congestive heart failure and muscular dystrophy hamsters by systemic gene transfer. Circulation 2005; 112: 2650-2659.
14. Pacak CA, Mah CS, Thattaliyath BD, Conlon TJ, Lewis MA, Cloutier DE et al. Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo. Circ Res 2006; 99 3-9.
15. Chirmule N, Xiao W, Truneh A, Schnell MA, Hughes JV, Zoltick P et al. Humoral immunity to adeno-associated virus type 2 vectors following administration to murine and nonhuman primate muscle. J Virol 2000; 74: 2420-2425.
16. Sandalon Z, Bruckheimer EM, Lustig KH, Burstein H. Long-term suppression of experimental arthritis following intramuscular administration of a pseudotyped AAV2/1-TNFR:FC vector. Mol Ther 2007; 15: 264-269.
17. Yu X, Patterson E, Huang S, Garrett MW, Kem DC. Tumor necrosis factor α rapid ventricular tachyarrhythmias, and infarct size in canine models of myocardial infarction. J Cardiovasc Pharmacol 2005; 45: 153-159.
18. Chirmule N, Propert K, Magosin S, Qian Y, Qian R, Wilson J. Immune responses to adenovirus and adeno-associated virus in humans. Gene Therapy 1999; 6: 1574-1583.
19. Anderson P, Louie J, Lau A, Broder M. Mechanisms of differential immunogenicity of tumor necrosis factor inhibitors. Curr Rheumatol Rep 2005; 7: 3-9.
20. Barrier BF, Bates GW, Leland MM, Leach DA, Robinson RD, Propst AM. Efficacy of anti-tumor necrosis factor therapy in the treatment of spontaneous endometriosis in baboons. Fertil Steril 2004; 81 (Suppl 1): 775-779.
21. Gao G, Lu Y, Calcedo R, Grant RL, Bell P, Wang L et al. Biology of AAV serotype vectors in liver-directed gene transfer to nonhuman primates. Mol Ther 2006; 13: 77-87.
22. Herzog RW, Fields PA, Arruda VR, Brubaker JO, Armstrong E, McClintock D et al. Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy. Hum Gene Ther 2002; 13: 1281-1291.
23. Nathwani AC, Davidoff A, Hanawa H, Zhou JF, Vanin EF, Nienhuis AW. Factors influencing in vivo transduction by recombinant adeno-associated viral vectors expressing the human factor IX cDNA. Blood 2001; 97: 1258-1265.
24. Sarukhan A, Soudais C, Danos O, Jooss K. Factors influencing cross-presentation of non-self antigens expressed from recombinant adeno-associated virus vectors. J Gene Med 2001; 3: 260-270.
25. Wang L, Dobrzynski E, Schlachterman A, Cao O, Herzog RW. Systemic protein delivery by muscle-gene transfer is limited by a local immune response. Blood 2005; 105: 4226-4234.
26. Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006; 12: 342-347.
27. Smith SC, Allen PM. Neutralization of endogenous tumor necrosis factor ameliorates the severity of myosin-induced myocarditis. Circ Res 1992; 70: 856-863.
28. Yamada T, Matsumori A, Sasayama S. Therapeutic effect of anti-tumor necrosis factor-alpha antibody on the murine model of viral myocarditis induced by encephalomyocarditis virus. Circulation 1994; 89: 846-851.
29. Korth-Bradley JM, Rubin AS, Hanna RK, Simcoe DK, Lebsack ME. The pharmacokinetics of etanercept in healthy volunteers. Ann Pharm 2000; 34: 161-164.
30. Kwon HJ, Cote TR, Cuffe MS, Kramer JM, Braun MM. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003; 138: 807-811.
31. Zeltser R, Valle L, Tanck C, Holyst MM, Ritchlin C, Gaspari AA. Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: A recombinant tumor necrosis factor alpha receptor: Fc fusion protein. Arch Derm 2001; 137: 893-899.
32. Herzog RW. Immune responses to AAV capsid: Are mice not humans after all? Mol Ther 2007; 15: 649-650.
33. Jacobs CA, Smith CA. Methods of lowering active TNF-alpha levels in mammals using tumor necrosis factor receptor. US Patent 5: 605-690, US Patent and Trademark Office, Washington DC, 1997.
34. Xiao X, Li J, Samulski RJ. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 1998; 72: 2224-2232.